补骨脂素和异补骨脂素与人免疫球蛋白的相互作用

将互为同分异构体的两种植物药活性组分补骨脂素和异补骨脂素作为研究对象, 应用荧光光谱法、紫外光谱法以及红外光谱法并结合分子对接技术对这两种香豆素类化合物与人-γ球蛋白(Human gammago-bulin, HG)的相互作用进行了比较研究. 荧光光谱法研究结果表明, 补骨脂素和异补骨脂素与蛋白之间均有较强的结合(结合常数位于0.251×10⁴～3.503×10⁴之间), 且对HG都表现为静态猝灭. 不同温度(298, 308和318 K)下两种药物与HG相互作用的结合参数均有所差别, 维持药物-蛋白质体系的作用力也不相同. 依据Förster能量转移理论, 得到补骨脂素和异补骨脂素分子与蛋白质色氨酸残基间的结合距离r值(分别为3.65和4.21 nm)都小于7 nm, 说明发生了能量转移. 利用同步荧光与红外光谱法研究了药物对蛋白质二级结构的影响. 分子对接研究结果表明, 这两种药物与蛋白有相似的结合区域和相同的结合模式.     

一种新型三氮唑化合物的光物理性质及其与血清白蛋白的键合研究

1-(1-萘基)-5-苯基-1H-1,2,3-三唑(1-(naphthalen-1-yl)-5-phenyl-1H-1,2,3-triazole, 简称NPTA)是一种新合成的三氮唑化合物, 研究了其光谱特征及其生物活性. 利用PM3半经验方法的Polak-Ribiere共轭梯度法得到了优化的NPTA分子结构, 进而用分子对接显示与人血清白蛋白(HSA)的键合模式及位点, 再利用紫外光谱、多种荧光光谱法等技术表征了NPTA及其键合HSA的光谱性质. 结果表明: 共轭多烯π键的存在使得NPTA呈现特征的荧光与紫外光谱. 分子模拟的结果表明NPTA可以嵌于HSA分子的疏水腔内, 并与精氨酸Arg222形成四个氢键; 位点竞争实验确定了NPTA在HSA亚结构域的位点II位发生作用. 二维及三维荧光光谱显示NPTA可以猝灭HSA的内源荧光, 使其构象发生变化; 紫外、同步荧光扫描证实NPTA主要猝灭了HSA色氨酸残基的荧光, 并影响了HSA的微环境; 较小的各向异性值说明NPTA与HSA结合后生成的配合物弛豫时间较短, 结合的较松. 荧光滴定法求得不同温度下(299, 309和319 K) NPTA与HSA作用的键合常数, 键合模式为典型的疏水作用, 与分子模拟的结果相一致. 另外, 测定了NPTA与键合HSA相关的几种物理化学参数.     

考拉维酸对人血清白蛋白结构的影响

利用多种荧光光谱法、紫外光谱法并结合分子模拟等方法, 表征了模拟生理条件下一种植物药活性组分考拉维酸(KA)影响人血清白蛋白(HSA)的结构信息. 同步荧光及紫外光谱证实考拉维酸的存在影响了HSA的微环境; 二维及三维荧光光谱表明考拉维酸可以猝灭HSA的内源荧光, 使其构象发生变化. 荧光偏振的测定提供了考拉维酸与HSA作用后生成的配合物弛豫时间与聚集特性的信息, 揭示KA的存在使HSA的流动性和微粘度发生变化. 定量求得不同温度下(298、308 和318 K)考拉维酸与HSA作用的键合参数和热力学参数. 分子模拟表明考拉维酸键合位点于HSA分子的疏水腔内, 并与赖氨酸Lys195 和天冬氨酸Asp451 形成三个氢键, 与HSA的键合模式主要是疏水作用; 位点竞争实验证明考拉维酸在HSA亚结构域的位点Ⅱ位发生作用. 另外, 获得的相关物理化学参数从分子水平上揭示了考拉维酸与HSA相互作用的机制. 结果表明, HSA对考拉维酸有较强的结合能力, 提示人血清白蛋白对考拉维酸可起到储存和转运的作用.     

考拉维酸对人血清白蛋白结构的影响

利用多种荧光光谱法、紫外光谱法并结合分子模拟等方法,表征了模拟生理条件下一种植物药活性组分考拉维酸(KA)影响人血清白蛋白(HSA)的结构信息.同步荧光及紫外光谱证实考拉维酸的存在影响了HSA的微环境;二维及三维荧光光谱表明考拉维酸可以猝灭HSA的内源荧光,使其构象发生变化.荧光偏振的测定提供了考拉维酸与HSA作用后生成的配合物弛豫时间与聚集特性的信息,揭示KA的存在使HSA的流动性和微粘度发生变化.定量求得不同温度下(298、308和318 K)考拉维酸与HSA作用的键合参数和热力学参数.分子模拟表明考拉维酸键合位点于HSA分子的疏水腔内,并与赖氨酸Lys195和天冬氨酸Asp451形成三个氢键,与HSA的键合模式主要是疏水作用;位点竞争实验证明考拉维酸在HSA亚结构域的位点II位发生作用.另外,获得的相关物理化学参数从分子水平上揭示了考拉维酸与HSA相互作用的机制.结果表明,HSA对考拉维酸有较强的结合能力,提示人血清白蛋白对考拉维酸可起到储存和转运的作用.     

1-(4-溴苯基)-5-苯基-1H-1,2,3-三氮唑键合人血清白蛋白的作用机制及抗菌活性

利用化学信息学、多种光谱法及抗菌实验,研究了1-(4-溴苯基)-5-苯基-1H-1,2,3-三唑(1-(4-bromophenyl)-5-phenyl-1H-1,2,3-triazole,BPTA)键合人血清白蛋白(HSA)的作用机制及抗菌活性。研究了BPTA的荧光光谱及紫外光谱;分子模拟确定了BPTA与HSA的键合区域和模式,位点竞争实验确定了BPTA在HSA亚结构域的位点Ⅱ发生作用。利用荧光偏振、紫外光谱、同步及三维荧光方法在模拟生理条件下研究了BPTA与HSA的作用机制及对蛋白微环境和二级结构的影响,并求得不同温度下BPTA与HSA作用的键合参数和热力学参数,确定了键合模式主要是疏水力作用、氢键及范德华作用。从分子水平上揭示了BPTA与HSA相互作用的机制,说明BPTA在生理条件下能被HSA载运至靶位发挥药效。另外,抗菌实验表明,BPTA对白色葡萄球菌、金黄色葡萄球菌、枯草芽孢杆菌、蜡状芽孢杆菌、四联球菌及白色念珠菌6种菌类均有明显的抑制作用。     

腺苷与人血清白蛋白间相互作用的荧光光谱及分子模型法研究

在模拟人体生理条件下,结合紫外光谱和分子对接模型运用荧光光谱研究了腺苷与人血清白蛋白(HSA)间的键合作用。腺苷有较强的能力猝灭人血清白蛋白的内源荧光,且根据Stern-Volmer方程判断出猝灭机制为静态猝灭。本文运用相应的荧光值和Vant’Hoff热力学方程求得了不同温度下的结合常数(K)以及一些热力学参数,如焓变(ΔH)和熵变(ΔS)。结果表明：键合过程中疏水作用力对新化合物的稳定性起主要作用,这与分子对接模型方法研究的结果基本一致。另外还研究了常见离子对结合常数的影响。     

丁咯地尔与人血清白蛋白结合的光谱学研究

用紫外吸收光谱法、荧光光谱法和傅立叶变换红外光谱法探讨了在模拟人体生理条件下,丁咯地尔与人血清白蛋白(HSA)的结合模式.结果表明:丁咯地尔对HSA的内源荧光有显著的猝灭作用,且猝灭机理主要为静态猝灭.丁咯地尔与HSA形成了1 ∶ 1的复合物,结合常数K=7.43×102 L·mol-1(308 K).根据Fster偶极-偶极非辐射能量转移机理,求得丁咯地尔与HSA间的结合距离r=2.64 nm.由热力学参数确定其作用力以氢键和范德华力为主.同步荧光和傅立叶变换红外光谱表明丁咯地尔对HSA二级结构的含量产生影响,使HSA的α-螺旋结构的含量明显降低,β-折叠和β-转角结构的含量增加.     

2'-羟基-2,4-二溴二苯醚与人血清白蛋白作用机制的光谱研究与计算模拟

采用分子对接、分子动力学模拟和光谱法研究了2'-羟基-2,4-二溴二苯醚(2'-OH-BDE-7)与人血清白蛋白(HSA)的相互作用.同步荧光光谱研究表明,2'-OH-BDE-7诱导HSA的构象产生变化,并与分子动力学模拟的结果相吻合.荧光光谱表明,2'-OH-BDE-7能引起HSA荧光猝灭,且其作用机制为静态猝灭和非辐射能量转移.热力学分析得出ΔG0,ΔH0和ΔS0,表明氢键和范德华力在HSA-2'-OH-BDE-7的体系中起着重要作用.竞争实验和分子对接结果表明2'-OH-BDE-7主要结合在HSA的位点Ⅰ.将计算模拟和光谱实验研究相结合,为研究小分子和蛋白质相互作用机制提供更多的信息.     

白藜芦醇类似物与人血清白蛋白的相互作用

采用荧光光谱、三维荧光光谱、紫外吸收光谱研究白藜芦醇类似物(Z)-2-(3,4-二甲氧苯基)-3-(4-二甲氨基苯基)丙烯腈(HCQ)与人血清白蛋白(HSA)的相互作用,探讨其作为抗肿瘤药物的可能。结果发现HCQ与HSA形成了基态配合物,HCQ主要结合于HSA的位点Ⅰ,与位点Ⅱ也有微量的结合,反应为自发的放热反应,其ΔH、ΔS、ΔG均小于零,二者之间的结合力为氢键或者范德华力,结合常数为104～105数量级。HCQ与HSA的结合使HSA构象发生变化,Trp-214所处的环境疏水性增加,使得其内源性荧光显著降低。说明合成的白藜芦醇类似物能够与人血清白蛋白结合。     

荧光与紫外光谱法研究柚皮素与人血清白蛋白的结合模式

在模拟生理条件下,利用荧光光谱法和紫外吸收光谱法研究了柚皮素(NG)与人血清白蛋白(HSA)的相互作用。实验结果表明,NG对HSA的内源性荧光具有猝灭作用,属于静态猝灭过程。计算了NG-HSA体系的结合常数、结合位点数及反应的热力学参数ΔG,ΔH和ΔS,由此推出二者主要通过氢键和范德华力自发形成了摩尔比为1∶1的非共价复合物。依据Frster非辐射能量转移理论求得二者之间的结合距离为3.41 nm。三维荧光、同步荧光光谱和结合位点取代实验指出,NG主要与HSA的III A亚结构域中site II位点的酪氨酸结合。     

光谱法测定伊曲康唑与牛血清和人血清白蛋白相互作用

用荧光光谱和紫外吸收光谱法, 在pH=7.4±0.1的0.1 mol·L-1磷酸缓冲溶液中, 研究了伊曲康唑与牛血清白蛋白(BSA)和人血清白蛋白(HSA)的相互作用. 实验结果表明, 伊曲康唑与牛血清白蛋白和人血清白蛋白作用的猝灭常数均随着温度的升高而降低, 伊曲康唑可以有规律地使血清白蛋白内源荧光猝灭, 其猝灭机理可认为是伊曲康唑与白蛋白形成复合物的静态猝灭. 获得了在不同温度下, 伊曲康唑与血清白蛋白作用的结合常数以及△G、△H和△S等热力学参数. 根据所得结果可推断伊曲康唑与白蛋白的作用力主要为疏水作用力, 同时, 利用荧光共振能量转移理论(FRET)计算得出了伊曲康唑与白蛋白结合位置的距离d. 而且, 利用同步荧光光谱和紫外光谱揭示了该反应中蛋白的结构和其微环境的变化.     

Investigation of the behavior of HSA upon binding to amlodipine and propranolol: Spectroscopic and molecular modeling approaches

The interaction between human serum albumin (HSA) and two drugs - amlodipine and propranolol - was investigated using fluorescence, UV absorption and circular dichroism (CD) spectroscopy. In addition, the binding site was established by applying molecular modeling technique. Fluorescence data suggest that amlodipine will quench the intrinsic fluorescence of HSA; whereas propranolol enhances the fluorescence of HSA. The binding constants for the interaction of amlodipine and propranolol with HSA were found to be 3.63×10(5)M(-1) and 2.29×10(4)M(-1), respectively. The percentage of secondary structure feature of each one of the HSA-bound drugs, i.e. the α-helix content, was estimated empirically by circular dichroism. The results indicated that amlodipine causes an increase, and that propranolol leads to a decrease in α-helix content of HSA. The spectroscopic analysis indicates that the binding mechanisms of the two drugs are different from each other. The data obtained by the molecular modeling study indicated that these drugs bind, with different affinity, to different sites located in subdomain IIA and IIIA.     

Binding of brucine to human serum albumin

The feature of brucine binding to human serum albumin (HSA) was investigated via fluorescence and UV/vis absorption spectroscopy. The results revealed that brucine caused the fluorescence quenching of HSA by the formation of brucine–HSA complex. The hydrophobic interaction plays a major role in stabilizing the complex; the binding site number n and apparent binding constant K_A, corresponding thermodynamic parameters the free energy change (ΔG), enthalpy change (ΔH) and entropy change (ΔS) at different temperatures were calculated. The distance r between donor (HSA) and acceptor (brucine) was obtained according to fluorescence resonance energy transfer. The effect of brucine on the conformation of HSA was analyzed using synchronous fluorescence spectroscopy and UV/vis absorption spectroscopy.     

Characterization of Gallic Acid Interaction with Human Serum Albumin by Spectral and Molecular Modeling Methods

The binding of drugs with human serum albumin(HSA)is a crucial factor influencing the distribution and bioactivity of drugs in the body.To understand the action mechanisms between gallic acid(GA,3,4,5-...     

Protein binding of quinolonecarboxylic acids. II. Spectral changes on the interaction of cinoxacin, nalidixic acid and pipemidic acid with human and rat albumins

The interaction of cinoxacin (CINX), nalidixic acid (NA), and pipemidic acid (PPA) with human and rat serum albumins (HSA and RSA) was studied by UV difference absorption and circular dichroism (CD) spectroscopy. CINX and NA bound to the albumins and generated difference absorption and induced CD (ICD) spectra. The difference absorption spectral data explained reasonably our previous observations that CINX bound to HSA more weakly than NA, but to RSA as strongly as NA. We used a quantity delta epsilon/epsilon, designated as relative molar difference absorbance, at positions corresponding to the longest wavelength peaks in the difference spectra. The quantity was found to correlate linearly with percent bound to both HSA and RSA, but with different slopes, from which the binding site for CINX and NA in RSA was supposed to provide a much more nonpolar environment than that in HSA. The magnitude of ICD bands observed at 371 nm for CINX and at 342-348 nm for NA corresponded to the binding degrees of these drugs to both albumins. Anisotropy factors for the ICD bands at 350-271 nm for CINX and 320-348 nm for NA were approximately similar between HSA and RSA, suggesting a similar ability to generate the ICD spectra in these wavelength regions upon binding to the albumins. Spectral results for PPA in albumin solutions showed little or no binding of this drug to HSA and RSA. PPA existed as a betaine form in neutral solution and its positively charged group acted as an unfavorable factor for binding to both albumins.     

Mechanism of interaction of hypoglycemic agents glimepiride and glipizide with human serum albumin

The mechanism of interaction of hypoglycemic drugs, glimepiride and glipizide with human serum albumin (HSA) has been studied using fluorescence spectroscopy. The results are discussed in terms of the binding parameters, thermodynamics of the binding process, nature of forces involved in the interaction, identification of drug binding site on serum albumin and the fluorescence quenching mechanism involved. The association constants were of the order of 10⁵ and glipizide was found to have much higher affinity for HSA than glimepiride at all temperatures. Thermodynamic parameters for the binding suggested that hydrophobic interactions are primarily involved in the binding of these drugs to HSA. However, glimepiride and glipizide appear to cause temperature-dependent conformational changes in the albumin molecule and, therefore, the nature of interaction varied with temperature. Glimepiride and glipizide bind to both site I and site II on HSA, but the primary interaction occurs at site II. The binding region in site II is different for the two drugs. Stern-Volmer analysis of quenching data indicated that tryptophan residues of HSA are not fully accessible to the drugs and a predominantly dynamic quenching mechanism is involved in the binding. Results can provide useful insight into prediction of competitive displacement of these drugs by other co-administered drugs and excipients, resulting in serious fluctuations of the blood glucose levels in diabetic patients.